Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $10,778,084.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Halozyme Therapeutics Stock Performance

Shares of HALO traded up $0.38 during midday trading on Wednesday, reaching $62.31. 1,175,859 shares of the stock were exchanged, compared to its average volume of 1,253,883. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The stock’s 50 day simple moving average is $57.96 and its 200 day simple moving average is $48.85. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $65.53. The company has a market cap of $7.93 billion, a P/E ratio of 25.59, a PEG ratio of 0.57 and a beta of 1.28.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.68 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current year.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its holdings in shares of Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares during the period. Rise Advisors LLC bought a new stake in Halozyme Therapeutics during the first quarter worth $25,000. International Assets Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at $33,000. Whittier Trust Co. acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at $27,000. Finally, Principal Securities Inc. bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $34,000. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HALO shares. HC Wainwright reiterated a “buy” rating and set a $65.00 price target on shares of Halozyme Therapeutics in a report on Friday, September 13th. TD Cowen boosted their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. cut their price target on Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Piper Sandler downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $48.00 to $51.00 in a report on Friday, June 7th. Finally, Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $59.44.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.